Compare M&T Bank Corporation (MTB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Sanofi SA — how do they compare? M&T Bank Corporation trades at $222.43 (market cap $31.28B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 3.1× M&T Bank Corporation's market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and Sanofi SA for 94 Days on average.
| MTB | SNY | |
|---|---|---|
Market Cap | $31.28B | $96.81B |
Volume | 934,561 | 2,081,815 |
Sector | Financials | Health |
52-Week High | $254.09 | $52.34 |
52-Week Low | $178.63 | $39.51 |
Typical Hold Time | 100 Days | 94 Days |
Enterprise Value | $47.64B | $116.20B |
Dividend Yield | 2.77% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $217.56, down 0.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows solid fundamentals with a P/E of 11.47, net income margin of 30.85%, and consistent earnings beats in recent quarters. Recent news highlights dividend strength, branch expansion, and AI-driven growth initiatives.
The stock offers a compelling value proposition with a consensus price target of $258.92 (18.9% upside), supported by loan growth and efficiency gains. Key risks include interest rate sensitivity and macroeconomic pressures. Analyst sentiment is mixed, with 31% buy ratings but a majority hold stance, reflecting cautious optimism amid a challenging rate environment.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
